Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Short NJ, et al. Among authors: kantarjian h. Lancet Haematol. 2024 Nov;11(11):e839-e849. doi: 10.1016/S2352-3026(24)00250-3. Epub 2024 Sep 17. Lancet Haematol. 2024. PMID: 39303729 Clinical Trial.
Natural history and staging of chronic myelogenous leukaemia.
Cortes J, Kantarjian HM, Giralt S, Talpaz M. Cortes J, et al. Among authors: kantarjian hm. Baillieres Clin Haematol. 1997 Jun;10(2):277-90. doi: 10.1016/s0950-3536(97)80007-8. Baillieres Clin Haematol. 1997. PMID: 9376664 Review.
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Jabbour E, et al. Among authors: kantarjian hm. Leukemia. 2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. Epub 2012 Nov 6. Leukemia. 2013. PMID: 23174881 Free PMC article.
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. DiNardo CD, et al. Among authors: kantarjian hm. Leukemia. 2014 Apr;28(4):958-61. doi: 10.1038/leu.2014.8. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24492324 Free PMC article. No abstract available.
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH. Walter RB, et al. Among authors: kantarjian hm. Leukemia. 2015 Feb;29(2):312-20. doi: 10.1038/leu.2014.242. Epub 2014 Aug 12. Leukemia. 2015. PMID: 25113226 Free PMC article.
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. Chen Z, et al. Among authors: kantarjian hm. Leukemia. 2016 Jul;30(7):1606-9. doi: 10.1038/leu.2016.6. Epub 2016 Feb 3. Leukemia. 2016. PMID: 26837843 Free PMC article. No abstract available.
2,549 results